The ALK inhibitor triggered responses in a significant minority of heavily pretreated patients, suggesting it can play a role in NSCLC treatment.

The antisense drug triggered a 20-point improvement against a score of neuropathy impairment, laying a marker for the upcoming showdown with Alnylam.

Roche will pay up to $387 million to license certain classes from the more than 100 groups of possibly novel antibiotics Warp Drive is analyzing.

Around a third of Trevena’s workforce are facing the ax as the biotech throws all its weight behind soon-to-be-filed injectable pain therapy Olinvo.

Ardelyx now has a second positive phase 3 trial for its constipation-predominant irritable bowel syndrome drug tenapanor.

Just months after its $80 million IPO, AnaptysBio is looking to raise another block of cash and accelerate development of its lead drug for eczema.

The $12.8 million equips the team to expand arms that are assessing different routes of administration of the IL13Rα2‐specific autologous CAR-T cells.

Sarepta is hoping to avoid the data-quality controversy that arose over its Duchenne muscular dystrophy drug Exondys51 last year with its next-generation drug…

The move sees Saha end his near-10-year spell away from Big Pharma for the chance to run Bristol-Myers’ translational medicine operation.

PanOptica plans to start trialling the small molecule anti-vascular endothelial growth factor eye drop early next year.